Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FG001 for Localization of Meningiomas or Low-Grade Gliomas
NCT06684795Phase 2
Key facts
- Status
- Recruiting
- Start
- May 2024
- Primary completion
- Jun 2026
- Countries
- 1
- Sponsor
- Rigshospitalet
- Modality
- Light/Condition-Responsive Prodrugs
- Drugs
- FG001
- Conditions
- meningiomaglioma
01
Overview
Phase 2, open-label trial of FG001 in meningioma and glioma (2 arms), sponsored by Rigshospitalet. Primary endpoint: Sensitivity for detection of tumor tissue at 24 months. Started May 2024; status: recruiting.
02
Design
2 arms- Study design
- Non-randomizedOpen-label
Presumed low-grade glioma
Patients with presumed low-grade glioma receiving FG001 prior to surgery
Meningioma
Patients with meningioma receiving FG001 prior to surgery
03
Who it enrols
Adult patients with MRI suggestive of meningioma or presumed low-grade glioma scheduled for neurosurgery, with normal organ function and no allergy to ICG.
04
Endpoints
Primary
Sensitivity for detection of tumor tissue
Secondary
Specificity for detection of tumor tissue
Tumor-to-Background Ratio
Incidence of Adverse Events
Beyond the preview
Go deeper on NCT06684795.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06684795.